Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

BACKGROUND Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens. METHODS We compared rituximab with cyclophosphamide as induction therapy in ANCA-associated vasculitis. We randomly assigned, in a 3:1 ratio, 44 patients with newly diagnosed ANCA-associated vasculitis and renal involvement to a standard glucocorticoid regimen plus either rituximab at a dose of 375 mg per square meter of body-surface area per week for 4 weeks, with two intravenous cyclophosphamide pulses (33 patients, the rituximab group), or intravenous cyclophosphamide for 3 to 6 months followed by azathioprine (11 patients, the control group). Primary end points were sustained remission rates at 12 months and severe adverse events. RESULTS The median age was 68 years, and the glomerular filtration rate (GFR) was 18 ml per minute per 1.73 m(2) of body-surface area. A total of 25 patients in the rituximab group (76%) and 9 patients in the control group (82%) had a sustained remission (P=0.68). Severe adverse events occurred in 14 patients in the rituximab group (42%) and 4 patients in the control group (36%) (P=0.77). Six of the 33 patients in the rituximab group (18%) and 2 of the 11 patients in the control group (18%) died (P=1.00). The median increase in the GFR between 0 and 12 months was 19 ml per minute in the rituximab group and 15 ml per minute in the control group (P=0.14). CONCLUSIONS A rituximab-based regimen was not superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis. Sustained-remission rates were high in both groups, and the rituximab-based regimen was not associated with reductions in early severe adverse events. (Funded by Cambridge University Hospitals National Health Service Foundation Trust and F. Hoffmann-La Roche; Current Controlled Trials number, ISRCTN28528813.)

[1]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. , 2010, Arthritis and rheumatism.

[2]  D. Altman,et al.  Analysing controlled trials with baseline and follow up measurements , 2001, BMJ : British Medical Journal.

[3]  A. Loft,et al.  Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. , 2008, The Journal of rheumatology.

[4]  Anastasia E. Raczek,et al.  The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. , 1992, Medical care.

[5]  C. Pusey,et al.  Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[7]  D. Furst,et al.  Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials , 2010 .

[8]  P. Emery,et al.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.

[9]  B. Haynes,et al.  Cyclophosphamide therapy of severe systemic necrotizing vasculitis. , 1979, The New England journal of medicine.

[10]  M. Falagas,et al.  Infectious complications of monoclonal antibodies used in cancer therapy , 2007, Cancer.

[11]  C. Gordon,et al.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.

[12]  R. Porter.  Nomenclature of Systemic Vasculitides: Proposal of an International Consensus Conference , 1995 .

[13]  A. Fauci,et al.  Suppression of human B lymphocyte function by cyclophosphamide. , 1982, Journal of immunology.

[14]  C. Kallenberg,et al.  Differential B- and T-cell activation in Wegener's granulomatosis. , 1999, The Journal of allergy and clinical immunology.

[15]  A. Feller,et al.  B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesions , 2005, Annals of the rheumatic diseases.

[16]  V. Tesar,et al.  Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis , 2009, Annals of Internal Medicine.

[17]  C. Kallenberg,et al.  Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. , 2006, Rheumatology.

[18]  Kenneth G. C. Smith,et al.  A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. , 2009, Arthritis and rheumatism.

[19]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[20]  J. Stone,et al.  Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. , 2005, Arthritis and rheumatism.

[21]  D. Revicki,et al.  Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. , 2008, The Journal of rheumatology.

[22]  David Steven Scott,et al.  Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.

[23]  R. Falk,et al.  Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. , 2006, Journal of the American Society of Nephrology : JASN.

[24]  Jianwen Cai,et al.  Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic AntibodyAssociated Small-Vessel Vasculitis , 2005, Annals of Internal Medicine.

[25]  S. Amadori,et al.  Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. , 2006, Rheumatology.

[26]  A. Müller,et al.  Is PR3‐ANCA Formation Initiated in Wegener's Granulomatosis Lesions? Granulomas as Potential Lymphoid Tissue Maintaining Autoantibody Production , 2005, Annals of the New York Academy of Sciences.

[27]  M. Krumbholz,et al.  BAFF is elevated in serum of patients with Wegener's granulomatosis. , 2005, Journal of autoimmunity.

[28]  Kenneth G. C. Smith,et al.  Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. , 2006, Arthritis and rheumatism.

[29]  Sabina A Antoniu.  Rituximab for refractory Wegener’s granulomatosis , 2006, Expert opinion on investigational drugs.

[30]  H. Raspe,et al.  Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force , 2007, Annals of the rheumatic diseases.

[31]  D. Jayne.  Role of rituximab therapy in glomerulonephritis. , 2010, Journal of the American Society of Nephrology : JASN.

[32]  H. Raspe,et al.  EULAR recommendations for the management of primary small and medium vessel vasculitis , 2008, Annals of the Rheumatic Diseases.

[33]  K. Chakravarty,et al.  BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. , 2007, Rheumatology.

[34]  V. Tesar,et al.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. , 2003, The New England journal of medicine.

[35]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[36]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Abramowicz,et al.  Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. , 2007, Journal of the American Society of Nephrology : JASN.

[38]  A. Steinberg,et al.  Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. , 1991, Arthritis and rheumatism.

[39]  D. Jayne,et al.  Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. , 2007, Kidney international.

[40]  C. Gordon,et al.  Malignancy is increased in ANCA-associated vasculitis. , 2004, Rheumatology.

[41]  L. Guillevin,et al.  Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. , 2008, Arthritis and rheumatism.

[42]  R. Panush.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis , 2011 .

[43]  B. Rovin,et al.  Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. , 2009, Clinical journal of the American Society of Nephrology : CJASN.